SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Y-mAbs Therapeutics, Inc. – ‘10-Q’ for 9/30/21 – ‘EX-101.SCH’

On:  Thursday, 11/4/21, at 3:14pm ET   ·   For:  9/30/21   ·   Accession #:  1558370-21-14548   ·   File #:  1-38650

Previous ‘10-Q’:  ‘10-Q’ on 8/9/21 for 6/30/21   ·   Next:  ‘10-Q’ on 5/9/22 for 3/31/22   ·   Latest:  ‘10-Q’ on 11/13/23 for 9/30/23   ·   4 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/04/21  Y-mAbs Therapeutics, Inc.         10-Q        9/30/21   76:7.4M                                   Toppan Merrill Bridge/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.27M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
12: R1          Document and Entity Information                     HTML     75K 
13: R2          Consolidated Balance Sheets                         HTML    116K 
14: R3          Consolidated Balance Sheets (Parenthetical)         HTML     34K 
15: R4          Consolidated Statements of Net Loss and             HTML     92K 
                Comprehensive Loss                                               
16: R5          Consolidated Statements of Changes in               HTML     95K 
                Stockholders' Equity                                             
17: R6          Consolidated Statements of Cash Flows               HTML     98K 
18: R7          Organization and Description of Business            HTML     24K 
19: R8          Basis of Presentation                               HTML     29K 
20: R9          Summary of Significant Accounting Policies          HTML     78K 
21: R10         Product Revenue                                     HTML     58K 
22: R11         Net Loss Per Share                                  HTML     48K 
23: R12         Inventory                                           HTML     38K 
24: R13         Accrued Liabilities                                 HTML     42K 
25: R14         License Agreements and Commitments                  HTML    150K 
26: R15         Stockholders' Equity                                HTML     33K 
27: R16         Share-Based Compensation                            HTML     92K 
28: R17         Related Party Transactions                          HTML     25K 
29: R18         Income Taxes                                        HTML     27K 
30: R19         Other Benefits                                      HTML     24K 
31: R20         Gain From Sale of Priority Review Voucher           HTML     24K 
32: R21         Summary of Significant Accounting Policies          HTML    104K 
                (Policies)                                                       
33: R22         Summary of Significant Accounting Policies          HTML     59K 
                (Tables)                                                         
34: R23         Product Revenue (Tables)                            HTML     52K 
35: R24         Net Loss Per Share (Tables)                         HTML     47K 
36: R25         Inventory (Tables)                                  HTML     39K 
37: R26         Accrued Liabilities (Tables)                        HTML     41K 
38: R27         License Agreements and Commitments (Tables)         HTML    141K 
39: R28         Share-Based Compensation (Tables)                   HTML     84K 
40: R29         BASIS OF PRESENTATION - Accumulated deficit         HTML     25K 
                (Details)                                                        
41: R30         BASIS OF PRESENTATION - Secondary public offering   HTML     34K 
                (Details)                                                        
42: R31         BASIS OF PRESENTATION - Cash and cash equivalents   HTML     24K 
                (Details)                                                        
43: R32         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     29K 
                Concentration of Credit Risk (Details)                           
44: R33         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair   HTML     40K 
                Value Measurement (Details)                                      
45: R34         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     49K 
                Revenue Recognition - License Revenue (Details)                  
46: R35         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     23K 
                Segment (Details)                                                
47: R36         PRODUCT REVENUE - Discounts and Allowances          HTML     59K 
                (Details)                                                        
48: R37         PRODUCT REVENUE - Concentrations (Details)          HTML     33K 
49: R38         NET LOSS PER SHARE - Basic and diluted (Details)    HTML     49K 
50: R39         NET LOSS PER SHARE - Anti-dilutive securities       HTML     23K 
                (Details)                                                        
51: R40         Inventory (Details)                                 HTML     28K 
52: R41         Accrued Liabilities (Details)                       HTML     36K 
53: R42         LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and  HTML     66K 
                MabVax License Agreement (Details)                               
54: R43         LICENSE AGREEMENTS AND COMMITMENTS - Other          HTML     40K 
                agreements (Details)                                             
55: R44         LICENSE AGREEMENTS AND COMMITMENTS - Lease          HTML     64K 
                agreements (Details)                                             
56: R45         LICENSE AGREEMENTS AND COMMITMENTS - Lease costs    HTML     31K 
                (Details)                                                        
57: R46         LICENSE AGREEMENTS AND COMMITMENTS - Lease          HTML     38K 
                maturities (Details)                                             
58: R47         LICENSE AGREEMENTS AND COMMITMENTS - Lease term     HTML     26K 
                and discount rate (Details)                                      
59: R48         STOCKHOLDERS' EQUITY - Authorized, Common and       HTML     40K 
                Preferred Stock (Details)                                        
60: R49         STOCKHOLDERS' EQUITY - Stock grant agreements with  HTML     77K 
                non-employees (Details)                                          
61: R50         STOCKHOLDERS' EQUITY - Issuance of common stock     HTML     38K 
                (Details)                                                        
62: R51         SHARE-BASED COMPENSATION - 2015 Plan (Details)      HTML     31K 
63: R52         SHARE-BASED COMPENSATION - 2018 Plan (Details)      HTML     41K 
64: R53         SHARE-BASED COMPENSATION - Stock option expense     HTML     34K 
                (Details)                                                        
65: R54         SHARE-BASED COMPENSATION - Stock option activity    HTML     64K 
                (Details)                                                        
66: R55         SHARE-BASED COMPENSATION - Stock option             HTML     28K 
                unrecognized compensation (Details)                              
67: R56         SHARE-BASED COMPENSATION - Restricted Stock Unit    HTML     62K 
                Activity (Details)                                               
68: R57         Related Party Transactions (Details)                HTML     39K 
69: R58         INCOME TAXES - Expense (Details)                    HTML     35K 
70: R59         INCOME TAXES - Uncertain tax positions (Details)    HTML     23K 
71: R60         Other Benefits (Details)                            HTML     29K 
72: R61         Gain From Sale of Priority Review Voucher           HTML     34K 
                (Details)                                                        
74: XML         IDEA XML File -- Filing Summary                      XML    135K 
11: XML         XBRL Instance -- ymab-20210930x10q_htm               XML   1.65M 
73: EXCEL       IDEA Workbook of Financial Reports                  XLSX     86K 
 7: EX-101.CAL  XBRL Calculations -- ymab-20210930_cal               XML    132K 
 8: EX-101.DEF  XBRL Definitions -- ymab-20210930_def                XML    529K 
 9: EX-101.LAB  XBRL Labels -- ymab-20210930_lab                     XML   1.10M 
10: EX-101.PRE  XBRL Presentations -- ymab-20210930_pre              XML    841K 
 6: EX-101.SCH  XBRL Schema -- ymab-20210930                         XSD    161K 
75: JSON        XBRL Instance as JSON Data -- MetaLinks              340±   491K 
76: ZIP         XBRL Zipped Folder -- 0001558370-21-014548-xbrl      Zip    302K

‘EX-101.SCH’   —   XBRL Schema — ymab-20210930

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created with Toppan Merrill Bridge 9.6.7908.23199 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 11/4/2021 7:05:15 PM -->
<!-- Modified on: 11/4/2021 7:05:15 PM -->
<xsd:schema targetNamespace="http://www.ymabs.com/20210930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ymab="http://www.ymabs.com/20210930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
<xsd:annotation>
<xsd:appinfo>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
<link:definition> 99900 - Disclosure - Standard And Custom Axis Domain Defaults </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
<link:definition> 00100 - Statement - Consolidated Balance Sheets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" id="StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss">
<link:definition> 00200 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
<link:definition> 00400 - Statement - Consolidated Statements of Cash Flows </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenueDiscountsAndAllowancesDetails" id="DisclosureProductRevenueDiscountsAndAllowancesDetails">
<link:definition> 40401 - Disclosure - PRODUCT REVENUE - Discounts and Allowances (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureInventoryDetails" id="DisclosureInventoryDetails">
<link:definition> 40601 - Disclosure - INVENTORY (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetailsCalc2" id="DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetailsCalc2">
<link:definition> 40608 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease maturities (Details) (calc 2) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesDetails">
<link:definition> 40701 - Disclosure - ACCRUED LIABILITIES (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetails" id="DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetails">
<link:definition> 40805 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease maturities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
<link:definition> 41101 - Disclosure - RELATED PARTY TRANSACTIONS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
<link:definition> 00300 - Statement - Consolidated Statements of Changes in Stockholders' Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsTables" id="DisclosureLicenseAgreementsAndCommitmentsTables">
<link:definition> 30803 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
<link:definition> 31003 - Disclosure - SHARE-BASED COMPENSATION (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureBasisOfPresentationSecondaryPublicOfferingDetails" id="DisclosureBasisOfPresentationSecondaryPublicOfferingDetails">
<link:definition> 40202 - Disclosure - BASIS OF PRESENTATION - Secondary public offering (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
<link:definition> 40302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails">
<link:definition> 40304 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurement (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionLicenseRevenueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionLicenseRevenueDetails">
<link:definition> 40305 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition - License Revenue (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenueConcentrationsDetails" id="DisclosureProductRevenueConcentrationsDetails">
<link:definition> 40402 - Disclosure - PRODUCT REVENUE - Concentrations (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails">
<link:definition> 40502 - Disclosure - NET LOSS PER SHARE - Anti-dilutive securities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsMskCd33AndMabvaxLicenseAgreementDetails" id="DisclosureLicenseAgreementsAndCommitmentsMskCd33AndMabvaxLicenseAgreementDetails">
<link:definition> 40801 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and MabVax License Agreement (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsOtherAgreementsDetails" id="DisclosureLicenseAgreementsAndCommitmentsOtherAgreementsDetails">
<link:definition> 40802 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Other agreements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseAgreementsDetails" id="DisclosureLicenseAgreementsAndCommitmentsLeaseAgreementsDetails">
<link:definition> 40803 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease agreements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseCostsDetails" id="DisclosureLicenseAgreementsAndCommitmentsLeaseCostsDetails">
<link:definition> 40804 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease costs (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseTermAndDiscountRateDetails" id="DisclosureLicenseAgreementsAndCommitmentsLeaseTermAndDiscountRateDetails">
<link:definition> 40806 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease term and discount rate (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStockholdersEquityStockGrantAgreementsWithNonEmployeesDetails" id="DisclosureStockholdersEquityStockGrantAgreementsWithNonEmployeesDetails">
<link:definition> 40902 - Disclosure - STOCKHOLDERS' EQUITY - Stock grant agreements with non-employees (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStockholdersEquityIssuanceOfCommonStockDetails" id="DisclosureStockholdersEquityIssuanceOfCommonStockDetails">
<link:definition> 40903 - Disclosure - STOCKHOLDERS' EQUITY - Issuance of common stock (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensation2015PlanDetails" id="DisclosureShareBasedCompensation2015PlanDetails">
<link:definition> 41001 - Disclosure - SHARE-BASED COMPENSATION - 2015 Plan (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensation2018PlanDetails" id="DisclosureShareBasedCompensation2018PlanDetails">
<link:definition> 41002 - Disclosure - SHARE-BASED COMPENSATION - 2018 Plan (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationStockOptionExpenseDetails" id="DisclosureShareBasedCompensationStockOptionExpenseDetails">
<link:definition> 41003 - Disclosure - SHARE-BASED COMPENSATION - Stock option expense (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" id="DisclosureShareBasedCompensationStockOptionActivityDetails">
<link:definition> 41004 - Disclosure - SHARE-BASED COMPENSATION - Stock option activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationStockOptionUnrecognizedCompensationDetails" id="DisclosureShareBasedCompensationStockOptionUnrecognizedCompensationDetails">
<link:definition> 41005 - Disclosure - SHARE-BASED COMPENSATION - Stock option unrecognized compensation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensationRestrictedStockUnitActivityDetails" id="DisclosureShareBasedCompensationRestrictedStockUnitActivityDetails">
<link:definition> 41006 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Unit Activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureOtherBenefitsDetails" id="DisclosureOtherBenefitsDetails">
<link:definition> 41301 - Disclosure - OTHER BENEFITS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureGainFromSaleOfPriorityReviewVoucherDetails" id="DisclosureGainFromSaleOfPriorityReviewVoucherDetails">
<link:definition> 41401 - Disclosure - GAIN FROM SALE OF PRIORITY REVIEW VOUCHER (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
<link:definition> 00090 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
<link:definition> 00105 - Statement - Consolidated Balance Sheets (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
<link:definition> 10101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
<link:definition> 10201 - Disclosure - BASIS OF PRESENTATION </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
<link:definition> 10301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenue" id="DisclosureProductRevenue">
<link:definition> 10401 - Disclosure - PRODUCT REVENUE </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
<link:definition> 10501 - Disclosure - NET LOSS PER SHARE </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureInventory" id="DisclosureInventory">
<link:definition> 10601 - Disclosure - INVENTORY </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureAccruedLiabilities" id="DisclosureAccruedLiabilities">
<link:definition> 10701 - Disclosure - ACCRUED LIABILITIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitments" id="DisclosureLicenseAgreementsAndCommitments">
<link:definition> 10801 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
<link:definition> 10901 - Disclosure - STOCKHOLDERS' EQUITY </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
<link:definition> 11001 - Disclosure - SHARE-BASED COMPENSATION </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
<link:definition> 11101 - Disclosure - RELATED PARTY TRANSACTIONS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
<link:definition> 11201 - Disclosure - INCOME TAXES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureOtherBenefits" id="DisclosureOtherBenefits">
<link:definition> 11301 - Disclosure - OTHER BENEFITS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureGainFromSaleOfPriorityReviewVoucher" id="DisclosureGainFromSaleOfPriorityReviewVoucher">
<link:definition> 11401 - Disclosure - GAIN FROM SALE OF PRIORITY REVIEW VOUCHER </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition> 20302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
<link:definition> 30303 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureProductRevenueTables" id="DisclosureProductRevenueTables">
<link:definition> 30403 - Disclosure - PRODUCT REVENUE (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
<link:definition> 30503 - Disclosure - NET LOSS PER SHARE (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
<link:definition> 30603 - Disclosure - INVENTORY (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
<link:definition> 30703 - Disclosure - ACCRUED LIABILITIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureBasisOfPresentationAccumulatedDeficitDetails" id="DisclosureBasisOfPresentationAccumulatedDeficitDetails">
<link:definition> 40201 - Disclosure - BASIS OF PRESENTATION - Accumulated deficit (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureBasisOfPresentationCashAndCashEquivalentsDetails" id="DisclosureBasisOfPresentationCashAndCashEquivalentsDetails">
<link:definition> 40203 - Disclosure - BASIS OF PRESENTATION - Cash and cash equivalents (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails">
<link:definition> 40307 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureNetLossPerShareBasicAndDilutedDetails" id="DisclosureNetLossPerShareBasicAndDilutedDetails">
<link:definition> 40501 - Disclosure - NET LOSS PER SHARE - Basic and diluted (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureStockholdersEquityAuthorizedCommonAndPreferredStockDetails" id="DisclosureStockholdersEquityAuthorizedCommonAndPreferredStockDetails">
<link:definition> 40901 - Disclosure - STOCKHOLDERS' EQUITY - Authorized, Common and Preferred Stock (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesExpenseDetails" id="DisclosureIncomeTaxesExpenseDetails">
<link:definition> 41201 - Disclosure - INCOME TAXES - Expense (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.ymabs.com/role/DisclosureIncomeTaxesUncertainTaxPositionsDetails" id="DisclosureIncomeTaxesUncertainTaxPositionsDetails">
<link:definition> 41202 - Disclosure - INCOME TAXES - Uncertain tax positions (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="ymab-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="ymab-20210930_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="ymab-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="ymab-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</xsd:appinfo>
</xsd:annotation>
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
<xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
<xsd:element id="ymab_NoncashStockIssuanceCostsToStrategicPartner" name="NoncashStockIssuanceCostsToStrategicPartner" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element name="IncreaseDecreaseInAccruedLiabilitiesAndOther" id="ymab_IncreaseDecreaseInAccruedLiabilitiesAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element name="NumberOfLicenseAgreements" id="ymab_NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
<xsd:element id="ymab_Cd33LicenseAgreementMember" name="Cd33LicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="SponsoredResearchAgreementMember" id="ymab_SponsoredResearchAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="MasterDataServicesAgreementMember" id="ymab_MasterDataServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_CoreFacilityServiceAgreementMember" name="CoreFacilityServiceAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LeasePayablePerMonth" name="LeasePayablePerMonth" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="OrganizationAndDescriptionOfBusinessAbstract" id="ymab_OrganizationAndDescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="BasisOfPresentationAbstract" id="ymab_BasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="AccruedClinicalCostsCurrent" id="ymab_AccruedClinicalCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element name="AccruedCompensationAndBoardFeesCurrent" id="ymab_AccruedCompensationAndBoardFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element name="TotalSharesAuthorized" id="ymab_TotalSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
<xsd:element name="NumberOfVotesPerCommonStock" id="ymab_NumberOfVotesPerCommonStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="OtherBenefitsDisclosureAbstract" id="ymab_OtherBenefitsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="OtherBenefitsDisclosureTextBlock" id="ymab_OtherBenefitsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_AccruedMilestoneAndRoyaltyPaymentsNoncurrent" name="AccruedMilestoneAndRoyaltyPaymentsNoncurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="EquityIncentivePlan2015Member" id="ymab_EquityIncentivePlan2015Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" id="ymab_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LeaseArrangementCorporateHeadquartersNewYorkMember" name="LeaseArrangementCorporateHeadquartersNewYorkMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LeaseArrangementOfficeSpaceDenmarkMember" name="LeaseArrangementOfficeSpaceDenmarkMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="ShareholderMskMember" id="ymab_ShareholderMskMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="FixedRentPayablePerAnnum" id="ymab_FixedRentPayablePerAnnum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="ymab_LicenseAndOtherAgreementsMember" name="LicenseAndOtherAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="OwnershipVotingPower" id="ymab_OwnershipVotingPower" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant"/>
<xsd:element name="OptionPriceAsPercentageOfFairMarketValueOfCommonStockOnGrantDate" id="ymab_OptionPriceAsPercentageOfFairMarketValueOfCommonStockOnGrantDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="EquityIncentivePlan2018Member" id="ymab_EquityIncentivePlan2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="GranteeOwningMoreThanTenPercentOfVotingPowerMember" id="ymab_GranteeOwningMoreThanTenPercentOfVotingPowerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="AccruedManufacturingCostsCurrent" id="ymab_AccruedManufacturingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant"/>
<xsd:element id="ymab_LeaseArrangementLaboratoryNewJerseyMember" name="LeaseArrangementLaboratoryNewJerseyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ResearchersEmployeesOfMskMember" name="ResearchersEmployeesOfMskMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_NumberOfIndividuals" name="NumberOfIndividuals" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_LicenseAgreementsAndCommitmentsAbstract" name="LicenseAgreementsAndCommitmentsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeClinicalMilestonePaymentsDue" name="ArrangementOtherThanCollaborativeClinicalMilestonePaymentsDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeRegulatoryMilestonePaymentsDue" name="ArrangementOtherThanCollaborativeRegulatoryMilestonePaymentsDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeSalesBasedMilestonePaymentsDue" name="ArrangementOtherThanCollaborativeSalesBasedMilestonePaymentsDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeResearchServicePeriod" name="ArrangementOtherThanCollaborativeResearchServicePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeNumberOfServiceAgreements" name="ArrangementOtherThanCollaborativeNumberOfServiceAgreements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_GrossProceedsFromIssuanceOfShares" name="GrossProceedsFromIssuanceOfShares" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_SadaLicenseAgreementMember" name="SadaLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeUpfrontPayment" name="ArrangementOtherThanCollaborativeUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="ymab_CompensationExpenseHealthInsuranceBenefits" name="CompensationExpenseHealthInsuranceBenefits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_NotesReceivableTerm" name="NotesReceivableTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_NotesReceivableInterestRate" name="NotesReceivableInterestRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_OtherAgreementsMember" name="OtherAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_MskMember" name="MskMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_SublicenseAgreementMember" name="SublicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LeaseArrangementManufacturingFacilityIndianaMember" name="LeaseArrangementManufacturingFacilityIndianaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LesseeOperatingLeaseMonthlyAccessFee" name="LesseeOperatingLeaseMonthlyAccessFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent" name="AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_MskLicenseAgreementMember" name="MskLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LicenseAgreementGroupOneMember" name="LicenseAgreementGroupOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ArrangementOtherThanCollaborativeCashPayments" name="ArrangementOtherThanCollaborativeCashPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_MilestonesAbstract" name="MilestonesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_FinancialStatementInformationAbstract" name="FinancialStatementInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_LesseeOperatingLeaseAdditionalAccessFee" name="LesseeOperatingLeaseAdditionalAccessFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_LesseeOperatingLeaseInitialFeeAndAccessFee" name="LesseeOperatingLeaseInitialFeeAndAccessFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_PriorityReviewVoucherMember" name="PriorityReviewVoucherMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_DisposalGroupNotDiscontinuedOperationPercentageOfNetProceedsFromMonetizationToBeRetained" name="DisposalGroupNotDiscontinuedOperationPercentageOfNetProceedsFromMonetizationToBeRetained" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_DisposalGroupNotDiscontinuedOperationPercentageOfNetProceedsFromMonetizationToBePaid" name="DisposalGroupNotDiscontinuedOperationPercentageOfNetProceedsFromMonetizationToBePaid" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_PublicOfferingFebruary2021Member" name="PublicOfferingFebruary2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_PublicOfferingFebruary2021UnderwritersOptionMember" name="PublicOfferingFebruary2021UnderwritersOptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_AreaOfRealEstatePropertyAdditional" name="AreaOfRealEstatePropertyAdditional" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"/>
<xsd:element id="ymab_DevelopmentAndCommercializationArrangementMember" name="DevelopmentAndCommercializationArrangementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ScicloneInternationalPharmaceuticalsLtdMember" name="ScicloneInternationalPharmaceuticalsLtdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_NumberOfCustomers" name="NumberOfCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"/>
<xsd:element id="ymab_AccruedSalesReservesCurrent" name="AccruedSalesReservesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ProductDanyelzaMember" name="ProductDanyelzaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_AdiumPharmaS.aMember" name="AdiumPharmaS.aMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_WholesalerOneMember" name="WholesalerOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_WholesalerTwoMember" name="WholesalerTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_DevelopmentAndCommercializationArrangementMilestonePaymentAchieved" name="DevelopmentAndCommercializationArrangementMilestonePaymentAchieved" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="ymab_ReserveForDiscountsAndAllowancesTableTextBlock" name="ReserveForDiscountsAndAllowancesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_NumberOfWholesaleCustomers" name="NumberOfWholesaleCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="ymab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsRemainingPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsRemainingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant"/>
<xsd:element id="ymab_ReservesForDiscountsAndAllowancesRollForward" name="ReservesForDiscountsAndAllowancesRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_ReserveForDiscountsBalance" name="ReserveForDiscountsBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ReserveForDiscountsAdditions" name="ReserveForDiscountsAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="ymab_ReserveForDiscountsReduction" name="ReserveForDiscountsReduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_SalesReturnLiabilityAdditions" name="SalesReturnLiabilityAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="ymab_SalesReturnLiabilityReduction" name="SalesReturnLiabilityReduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_ReservesAndAllowancesBalance" name="ReservesAndAllowancesBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="ymab_ReservesAndAllowancesAdditions" name="ReservesAndAllowancesAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"/>
<xsd:element id="ymab_ReservesAndAllowancesReductions" name="ReservesAndAllowancesReductions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="ymab_FinancialStatementAccruedLiabilitiesMember" name="FinancialStatementAccruedLiabilitiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="ymab_FinancialStatementAccountsReceivableMember" name="FinancialStatementAccountsReceivableMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold" id="ymab_RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ThreeCustomersMember" id="ymab_ThreeCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ContractualAllowanceAndGovernmentRebateLiabilityBalance" id="ymab_ContractualAllowanceAndGovernmentRebateLiabilityBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ContractualAllowanceAndGovernmentRebateLiabilityAdditions" id="ymab_ContractualAllowanceAndGovernmentRebateLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="ContractualAllowanceAndGovernmentRebateLiabilityReduction" id="ymab_ContractualAllowanceAndGovernmentRebateLiabilityReduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="ArrangementOtherThanCollaborativeTimeBasedMilestoneAccrualPeriod" id="ymab_ArrangementOtherThanCollaborativeTimeBasedMilestoneAccrualPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false"/>
</xsd:schema>

4 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/06/21  Y-mAbs Therapeutics, Inc.         10-Q        3/31/21   76:6.3M                                   Toppan Merrill Bridge/FA
11/05/20  Y-mAbs Therapeutics, Inc.         10-Q        9/30/20   68:6.7M                                   Toppan Merrill Bridge/FA
 9/26/18  Y-mAbs Therapeutics, Inc.         8-K:5,7,9   9/25/18    4:284K                                   Toppan Merrill/FA
 8/24/18  Y-mAbs Therapeutics, Inc.         S-1                   31:12M                                    Toppan Merrill-FA
↑Top
Filing Submission 0001558370-21-014548   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 1, 3:33:56.1am ET